Parkinson’s disease (PD) medication should adhere to the principle of “a long and thin stream, not to seek full effect”, in the dose of medication, the “minimum dose to reach a satisfactory effect”. Both general principles should be followed and individualization should be emphasized. Once diagnosed with PD, early protective therapy, such as selegiline, should be carried out. Coenzyme Q10 can also be used routinely and has been shown to significantly delay functional deterioration in dyskinesia. Early PD treatment, less than 65 years old, without cognitive dysfunction, can choose DR receptor agonists, such as Tessuta, Senforo; can also use Silegiran; even with compound levodopa, with psychiatric symptoms, with caution; with anisotropic patients can be added adamantadine; when the tremor is difficult to control, the anticholinergic drug antanxan (phenylephrine hydrochloride) can be chosen, with caution for people with glaucoma, prostate hypertrophy, cognitive dysfunction, and the elderly Use with caution in the elderly. Compound levodopa is preferred for patients older than 65 years of age, with DR agonists such as Senflo, Tazodar, etc., if necessary, and Antan is not used in older men unless severe tremor interferes with life. Patients with intermediate stage PD usually need to add compound levodopa, increase the dosage of DR agonists, or add amantadine. Late stage, PD performance is very complex, in addition to adverse drug reactions, the disease itself is also progressing, late treatment is very difficult, there is no extremely effective method, so early standardized treatment is particularly important. The main principle of advanced stage is to continue to control motor symptoms on the one hand, on the other hand, the treatment of non-motor complications, such as psychiatric symptoms, insomnia, phytoneurological dysfunction, anisocoria and so on have appropriate drugs. If the disease has lasted for more than 5 years, the efficacy of drugs is gradually decreasing, and it is still difficult to achieve the desired goal with increasing drug dosage, brain pacemaker therapy can be considered.